Abstract:Glioblastoma (GB) is the most aggressive and common type of cancer within the central nervous system (CNS). Despite the vast knowledge of its physiopathology and histology, its etiology at the molecular level has not been completely understood. Thus, attaining a cure has not been possible yet and it remains one of the deadliest types of cancer. Usually, GB is diagnosed when some symptoms have already been presented by the patient. This diagnosis is commonly based on a physical exam and imaging studies, such as computed tomography (CT) and magnetic resonance imaging (MRI), together with or followed by a surgical biopsy. As these diagnostic procedures are very invasive and often result only in the confirmation of GB presence, it is necessary to develop less invasive diagnostic and prognostic tools that lead to earlier treatment to increase GB patients' quality of life. Therefore, blood-based biomarkers (BBBs) represent excellent candidates in this context. microRNAs (miRNAs) are small, non-coding RNAs that have been demonstrated to be very stable in almost all body fluids, including saliva, serum, plasma, urine, cerebrospinal fluid (CFS), semen, and breast milk. In addition, serum-circulating and exosome-contained miRNAs have been successfully used to better classify subtypes of cancer at the molecular level and make better choices regarding the best treatment for specific cases. Moreover, as miRNAs regulate multiple target genes and can also act as tumor suppressors and oncogenes, they are involved in the appearance, progression, and even chemoresistance of most tumors. Thus, in this review, we discuss how dysregulated miRNAs in GB can be used as early diagnosis and prognosis biomarkers as well as molecular markers to subclassify GB cases and provide more personalized treatments, which may have a better response against GB. In addition, we discuss the therapeutic potential of miRNAs, the current challenges to their clinical application, and future directions in the field.

MicroRNAs as prognostic markers and therapeutic targets in gliomas

The role of microRNA in the pathogenesis of glial brain tumors

A Predicted Mir-27A-mediated Network Identifies a Signature of Glioma.

MicroRNA in Human Glioma.

Use of microRNAs as Diagnostic, Prognostic, and Therapeutic Tools for Glioblastoma

miRNAs role in glioblastoma pathogenesis and targeted therapy: Signaling pathways interplay

MicroRNAs Regulate Cell Cycle and Cell Death Pathways in Glioblastoma

MicroRNAs in meningiomas: Potential biomarkers and therapeutic targets

Role of MicroRNAs in Malignant Glioma

MicroRNAs involved in the EGFR pathway in glioblastoma

Unlocking the Potential of Circulating miRNAs as Biomarkers in Glioblastoma

Advance of MicroRNAs Research in Gliomas

MicroRNAs in adult high-grade gliomas: Mechanisms of chemotherapeutic resistance and their clinical relevance

Perspective of MiRNAs in Clinical Glioblastoma Research

MicroRNA Signatures Predict Prognosis of Patients with Glioblastoma Multiforme Through the Cancer Genome Atlas.

MicroRNAs, Key Regulators in Glioma Progression as Potential Therapeutic Targets for Chinese Medicine

Molecular mechanisms of microRNAs in glioblastoma pathogenesis

Micro RNA Molecules as Modulators of Treatment Resistance, Immune Checkpoints Controllers and Sensitive Biomarkers in Glioblastoma Multiforme

Identify Signature Regulatory Network for Glioblastoma Prognosis by Integrative Mrna and Mirna Co-Expression Analysis.

Establishment of a Prognostic-Related Micrornas Risk Model for Glioma by Bioinformatics Analysis

Comprehensive analysis of microglia gene and subpathway signatures for glioma prognosis and drug screening: linking microglia to glioma